Table 2 Changes in auxological parameter after GnRHa treatment or GnRHa + GH combination treatment.

From: Effect of gonadotropin-releasing hormone agonist monotherapy and combination therapy with growth hormone on final adult height in girls with central precocious puberty

Variable

GnRHa (n = 188)

GnRHa + GH (n = 22)

P-value

1 year after treatment

 Height(cm)

138.84 ± 5.00

136.29 ± 4.27

0.023

 Height SDS

1.06 ± 0.72

0.60 ± 0.83

0.006

 PAH (cm)

158.76 ± 5.29

154.52 ± 4.73

 < 0.001

 PAH SDS

−0.42 ± 1.06

−1.29 ± 0.99

 < 0.001

At end of treatment

 Height (cm)

149.28 ± 5.02

147.89 ± 4.83

0.346

 Height SDS

0.50 ± 0.77

0.37 ± 0.73

0.278

 PAH (cm)

166.25 ± 5.26

164.07 ± 4.99

0.067

 PAH SDS

1.04 ± 1.00

0.63 ± 0.95

0.068

At final adult height

 FAH (cm)

161.07 ± 4.78

159.63 ± 3.86

0.174

 Height SDS

−0.09 ± 0.94

−0.23 ± 0.77

0.530

  1. GnRHa Gonadotropin-releasing hormone agonist, GH Growth hormone, CA Chronological age, BA Bone age, SDS Standard deviation score, BMI Body mass index, PAH Predicted adult height-calculated with advanced table of baley–Pinneau (BP) method, FAH Final adult height.
Back to article page